Nine other pharmaceutical multinationals bow to Trump and will lower their prices in the United States

There are several American laboratories, such as Amgen, Bristol-Myers Squibb (BMS), Gilead and MSD. But also Europeans, like Boehringer Ingelheim, GSK, Novartis, Roche (owner of Genentech) and Sanofi.

Thus, these companies join Pfizer, AstraZeneca, Novo Nordisk and Lillywhich had already made similar pacts with the White House. In exchange for lower prices, drugs that these pharmaceutical companies sell in the United States (and are manufactured outside of this country) will not be subject to tariffs.

In any case, It should be remembered that these tariffs are not yet implemented. Even if Donald Trump has continued to threaten them.

“These agreements reduce the prices of drugs that treat many chronic and costly diseases, such as type 2 diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, HIV and certain types of cancer, among others,” the White House boasts in a statement.

The administration headed by Donald Trump boasts that thanks to the agreements there will be “trillions of dollars in savings”. Moreover, heensures that foreign countries can no longer use price controls to take advantage of American innovationguaranteeing most favored country prices on all new innovative medicines that the nine companies bring to market.

All companies They will have to sell via the TrumpRx platform. And they will do it with discounts often greater than 50%.

They will also have to donate the drugs they manufacture to the Strategic Reserve of Active Pharmaceutical Ingredients (Sapiri) “for reduce dependence on foreign countries and ensure that the United States has an adequate supply of such products in the event of an emergency.”